CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies
暂无分享,去创建一个
C. Dunbar | D. Couriel | E. Read | M. Cottler-Fox | D. Mavroudis | C. Carter | J. Molldrem | J. Barrett | M. Yu
[1] L. Schwartzberg,et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.
[2] R. Jacobs,et al. Combined transplantation of allogeneic bone marrow and CD34+ blood cells. , 1995, Blood.
[3] R. Storb,et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Andreeff,et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. , 1995, Blood.
[5] Gordon My,et al. Some factors determining the minimum number of cells required for successful clinical engraftment. , 1995 .
[6] H. Heimpel,et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. , 1995, Bone marrow transplantation.
[7] L. Terstappen,et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. , 1995, Blood.
[8] A. Winkelstein,et al. Enumeration of CD34+ hematopoietic stem cells for reconstitution following myeloablative therapy. , 1994, Cytometry.
[9] M. Cottler-Fox,et al. Quality assurance in flow cytometry: comparison of three analytical methods for quantifying CD34+ cells in marrow. , 1994, Progress in clinical and biological research.
[10] G. Reaman,et al. Extended-cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation. , 1993, Blood.
[11] M. Baccarani,et al. The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications. , 1992, Haematologica.
[12] L. To,et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. , 1992, Bone marrow transplantation.
[13] B. Glass,et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. , 1992, Blood.
[14] D. Printz,et al. CD34-positive cell proportions in peripheral blood correlate with colony-forming capacity. , 1991, Experimental hematology.
[15] R. Miller,et al. Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplant recipients. , 1987, Blood.
[16] H. Heimpel,et al. Hemopoietic reconstitution after bone marrow transplantation. , 1986, Experimental hematology.
[17] J. Biggs,et al. Lack of correlation between nucleated bone marrow cell dose, marrow CFU‐GM dose or marrow CFU‐E dose and the rate of HLA‐identical sibling marrow engraftment , 1985, British journal of haematology.
[18] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[19] T. Makinodan,et al. Mortality of mice as affected by variation of the x-ray dose and number of nucleated rat bone marrow cells injected. , 1957, Cancer research.